AU2015365602B2 - PARG inhibitory compounds - Google Patents
PARG inhibitory compounds Download PDFInfo
- Publication number
- AU2015365602B2 AU2015365602B2 AU2015365602A AU2015365602A AU2015365602B2 AU 2015365602 B2 AU2015365602 B2 AU 2015365602B2 AU 2015365602 A AU2015365602 A AU 2015365602A AU 2015365602 A AU2015365602 A AU 2015365602A AU 2015365602 B2 AU2015365602 B2 AU 2015365602B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- methylcyclopropyl
- sulfonamide
- oxo
- benzimidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c(cc1[N+]([O-])=O)ccc1Cl Chemical compound *c(cc1[N+]([O-])=O)ccc1Cl 0.000 description 3
- DRRWQXDCWXWGNN-UHFFFAOYSA-N CC1(CC1)NS(c(cc1)cc([N+]([O-])=O)c1Cl)(=O)=O Chemical compound CC1(CC1)NS(c(cc1)cc([N+]([O-])=O)c1Cl)(=O)=O DRRWQXDCWXWGNN-UHFFFAOYSA-N 0.000 description 2
- UPKJZHJHTJZCCB-UHFFFAOYSA-N C#CCN(c(ccc(S(NC1(CF)CC1)(=O)=O)c1)c1N1c2nnc(C(F)F)[s]2)C1=O Chemical compound C#CCN(c(ccc(S(NC1(CF)CC1)(=O)=O)c1)c1N1c2nnc(C(F)F)[s]2)C1=O UPKJZHJHTJZCCB-UHFFFAOYSA-N 0.000 description 1
- CXVJKFUVGRNMBM-UHFFFAOYSA-N CC1(CC1)NS(c(cc(c(N1C)c2)N(C(SC)=N)C1=O)c2F)(=O)=O Chemical compound CC1(CC1)NS(c(cc(c(N1C)c2)N(C(SC)=N)C1=O)c2F)(=O)=O CXVJKFUVGRNMBM-UHFFFAOYSA-N 0.000 description 1
- OSCDNXGKRSZJCP-ONEGZZNKSA-N CC1(CC1)NS(c(cc1)cc(N2c3ccc(/C=C/C)[o]3)c1NC2=O)(=O)=O Chemical compound CC1(CC1)NS(c(cc1)cc(N2c3ccc(/C=C/C)[o]3)c1NC2=O)(=O)=O OSCDNXGKRSZJCP-ONEGZZNKSA-N 0.000 description 1
- RAPJRICLBGLPBZ-UHFFFAOYSA-N CC1(CC1)NS(c(cc1)cc2c1c(C(c(cc1)ccc1F)=O)c[nH]2)(=O)=O Chemical compound CC1(CC1)NS(c(cc1)cc2c1c(C(c(cc1)ccc1F)=O)c[nH]2)(=O)=O RAPJRICLBGLPBZ-UHFFFAOYSA-N 0.000 description 1
- BUTBPZJMPPIAHX-UHFFFAOYSA-N CC1(CC1)NS(c(cc1C(F)(F)F)cc(N2c3nnc(C)[s]3)c1N(C)C2=O)(=O)=O Chemical compound CC1(CC1)NS(c(cc1C(F)(F)F)cc(N2c3nnc(C)[s]3)c1N(C)C2=O)(=O)=O BUTBPZJMPPIAHX-UHFFFAOYSA-N 0.000 description 1
- BZNWVJWSXBOZCV-UHFFFAOYSA-N CC1(CC1)NS(c1cc([N+]([O-])=O)c(C)cc1)(=O)=O Chemical compound CC1(CC1)NS(c1cc([N+]([O-])=O)c(C)cc1)(=O)=O BZNWVJWSXBOZCV-UHFFFAOYSA-N 0.000 description 1
- XFQMTKCQALLPSF-UHFFFAOYSA-N CC1(CC1)NS(c1ccc(c(C(C2CC2)=O)c[n]2-c3nnc(C)[s]3)c2c1)(=O)=O Chemical compound CC1(CC1)NS(c1ccc(c(C(C2CC2)=O)c[n]2-c3nnc(C)[s]3)c2c1)(=O)=O XFQMTKCQALLPSF-UHFFFAOYSA-N 0.000 description 1
- LNIRWOHKBUGVTQ-UHFFFAOYSA-N CC1(CC1)NS(c1ccc(c(Cc(cc2)ccc2F)c[n]2-c3nnc(C)[s]3)c2c1)(=O)=O Chemical compound CC1(CC1)NS(c1ccc(c(Cc(cc2)ccc2F)c[n]2-c3nnc(C)[s]3)c2c1)(=O)=O LNIRWOHKBUGVTQ-UHFFFAOYSA-N 0.000 description 1
- VZNKRNHJZJFKLX-UHFFFAOYSA-N CCC1(CC1)NS(c(cc1)cc(N2c3nnc(C)[s]3)c1N(CCOC)C2=O)(=O)=O Chemical compound CCC1(CC1)NS(c(cc1)cc(N2c3nnc(C)[s]3)c1N(CCOC)C2=O)(=O)=O VZNKRNHJZJFKLX-UHFFFAOYSA-N 0.000 description 1
- GOYBCWBXXCBQEQ-UHFFFAOYSA-N CCCN(c(cc(c(S(NC1(C)CC1)(=O)=O)c1)F)c1N1c2nnc(C)[o]2)C1=O Chemical compound CCCN(c(cc(c(S(NC1(C)CC1)(=O)=O)c1)F)c1N1c2nnc(C)[o]2)C1=O GOYBCWBXXCBQEQ-UHFFFAOYSA-N 0.000 description 1
- AWJMAOMQVYVZLT-UHFFFAOYSA-N CCCN(c(cc(cc1)F)c1N1c2nnc(C(C)F)[s]2)C1=O Chemical compound CCCN(c(cc(cc1)F)c1N1c2nnc(C(C)F)[s]2)C1=O AWJMAOMQVYVZLT-UHFFFAOYSA-N 0.000 description 1
- HYTOPECXURUEDC-UHFFFAOYSA-N CCN(CCO1)C1=C Chemical compound CCN(CCO1)C1=C HYTOPECXURUEDC-UHFFFAOYSA-N 0.000 description 1
- DALUCNUGMDNXET-UHFFFAOYSA-N CCc1c(C)nc(C)[s]1 Chemical compound CCc1c(C)nc(C)[s]1 DALUCNUGMDNXET-UHFFFAOYSA-N 0.000 description 1
- UUVUHCAHXNGVLI-UHFFFAOYSA-N CN(c(cc(cc1)F)c1N1)C1=O Chemical compound CN(c(cc(cc1)F)c1N1)C1=O UUVUHCAHXNGVLI-UHFFFAOYSA-N 0.000 description 1
- BSVREEFIRRQEKK-UHFFFAOYSA-N Cc1n[s]c(N(c2cc(S(NC3(CF)CC3)(=O)=O)ccc2N2)C2=O)n1 Chemical compound Cc1n[s]c(N(c2cc(S(NC3(CF)CC3)(=O)=O)ccc2N2)C2=O)n1 BSVREEFIRRQEKK-UHFFFAOYSA-N 0.000 description 1
- CIYBHQVKZRLUSP-UHFFFAOYSA-N Cc1nnc(N(c2ccccc2N2)C2=O)[s]1 Chemical compound Cc1nnc(N(c2ccccc2N2)C2=O)[s]1 CIYBHQVKZRLUSP-UHFFFAOYSA-N 0.000 description 1
- DPIZKMGPXNXSGL-UHFFFAOYSA-N Nc(cc1)cc(N)c1[N+]([O-])=O Chemical compound Nc(cc1)cc(N)c1[N+]([O-])=O DPIZKMGPXNXSGL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422771 | 2014-12-19 | ||
| GB1422771.4 | 2014-12-19 | ||
| PCT/GB2015/054064 WO2016097749A1 (en) | 2014-12-19 | 2015-12-17 | Parg inhibitory compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015365602A1 AU2015365602A1 (en) | 2017-06-29 |
| AU2015365602B2 true AU2015365602B2 (en) | 2020-02-27 |
Family
ID=54937310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015365602A Active AU2015365602B2 (en) | 2014-12-19 | 2015-12-17 | PARG inhibitory compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10508086B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3233845B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6673920B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102682782B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107295799B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015365602B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017012707B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2969298C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2886471T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL252745B (cg-RX-API-DMAC7.html) |
| MA (1) | MA41179A (cg-RX-API-DMAC7.html) |
| MX (1) | MX380901B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2017125520A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201704843QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016097749A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201704383B (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| US12491188B2 (en) | 2019-03-29 | 2025-12-09 | Board Of Regents, The University Of Texas System | Small molecule PARG inhibitors and methods of use thereof |
| TWI873187B (zh) * | 2019-09-20 | 2025-02-21 | 美商愛德亞生物科學公司 | 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物 |
| WO2023057389A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | Parg inhibitory compounds |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| EP4401721A4 (en) | 2021-10-17 | 2025-10-15 | Univ Of South Alabama Foundation For Research And Commercialization | CANCER TREATMENT |
| EP4479387A1 (en) | 2022-02-14 | 2024-12-25 | ARase Therapeutics Inc. | Inhibitors of parg |
| EP4488275A4 (en) | 2022-03-04 | 2025-07-23 | Shanghai Yingli Pharm Co Ltd | COMPOUND CONTAINING A FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023183850A1 (en) | 2022-03-23 | 2023-09-28 | Ideaya Biosciences, Inc. | Piperazine substituted indazole compounds as inhibitors of parg |
| CN114685283B (zh) * | 2022-04-06 | 2024-02-27 | 南京艾康生物科技有限公司 | 一种1-(氟甲基)环丙胺盐酸盐的制备方法 |
| WO2023205914A1 (en) * | 2022-04-28 | 2023-11-02 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| AU2023263181A1 (en) * | 2022-04-28 | 2024-10-31 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| AU2023271807A1 (en) | 2022-05-17 | 2025-01-02 | 858 Therapeutics, Inc. | Inhibitors of parg |
| KR20250028378A (ko) * | 2022-06-29 | 2025-02-28 | 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 | 5원 및 6원 융합 질소 함유 화합물, 이의 중간체, 제조 방법 및 용도 |
| KR20250034167A (ko) * | 2022-07-19 | 2025-03-10 | 에보포인트 바이오사이언시스 컴퍼니 리미티드 | 황 함유 헤테로방향족 고리 화합물, 이의 약학적 조성물 및 이의 용도 |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| AU2023355735A1 (en) | 2022-10-03 | 2025-04-03 | Forx Therapeutics Ag | Parg inhibitory compound |
| TW202417429A (zh) * | 2022-10-13 | 2024-05-01 | 南韓商韓美藥品股份有限公司 | 用於抑制yap-tead交互作用的新穎雜雙環化合物及包含其之藥學組成物 |
| WO2024120519A1 (zh) * | 2022-12-09 | 2024-06-13 | 捷思英达控股有限公司 | Tead抑制剂、其制备方法和在医学上的应用 |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2024222842A1 (en) * | 2023-04-27 | 2024-10-31 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| WO2024243304A2 (en) * | 2023-05-23 | 2024-11-28 | Quantx Biosciences Us, Inc. | Bicyclic heteroaryl compounds |
| WO2024254990A1 (zh) * | 2023-06-16 | 2024-12-19 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| TW202513045A (zh) * | 2023-08-10 | 2025-04-01 | 美商雅瑞斯醫療公司 | Parg抑制劑 |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1157858A (en) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Quinazoline derivatives |
| DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO2000030212A1 (en) | 1998-11-12 | 2000-05-25 | Bae Systems Electronics Limited | Scanning of electromagnetic beams |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL144745A0 (en) | 1999-02-10 | 2002-06-30 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| JP2004504391A (ja) | 2000-07-07 | 2004-02-12 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管新生阻害剤としてのコルキノール誘導体 |
| NZ522861A (en) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| PT1719773E (pt) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
| JP4995075B2 (ja) | 2004-03-25 | 2012-08-08 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用 |
| WO2007014226A2 (en) * | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Compounds for the treatment of neurodegeneration and stroke |
| ES2399112T3 (es) * | 2006-01-24 | 2013-03-25 | Eli Lilly & Company | Moduladores de INDOLSUFONAMIDA de receptores de PROGESTERONA |
| JP2009530342A (ja) | 2006-03-20 | 2009-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法 |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| JP2011500684A (ja) | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ，インコーポレイティド | ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物 |
| WO2010007944A1 (ja) * | 2008-07-17 | 2010-01-21 | 旭化成ファーマ株式会社 | 含窒素二環性複素環化合物 |
| CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
| CA2786999A1 (en) | 2010-01-13 | 2011-07-21 | Glaxosmithkline Llc | Compounds and methods |
| JP2013526484A (ja) | 2010-05-07 | 2013-06-24 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのアミノ‐キノリン |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| PH12013501489A1 (en) | 2010-12-17 | 2013-08-28 | Hoffmann La Roche | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| EP2471363A1 (de) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen |
| JP2014515368A (ja) | 2011-05-26 | 2014-06-30 | 第一三共株式会社 | プロテインキナーゼ阻害剤としての複素環化合物 |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| CA2896554C (en) | 2012-12-27 | 2019-11-05 | Drexel University | Novel antiviral agents against hbv infection |
| CN105980365B (zh) | 2014-02-11 | 2019-06-21 | 拜耳医药股份公司 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
| CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| US11104690B2 (en) | 2016-11-18 | 2021-08-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| US12491188B2 (en) | 2019-03-29 | 2025-12-09 | Board Of Regents, The University Of Texas System | Small molecule PARG inhibitors and methods of use thereof |
| TWI873187B (zh) | 2019-09-20 | 2025-02-21 | 美商愛德亞生物科學公司 | 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物 |
| WO2023057389A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2023183850A1 (en) | 2022-03-23 | 2023-09-28 | Ideaya Biosciences, Inc. | Piperazine substituted indazole compounds as inhibitors of parg |
-
2015
- 2015-12-16 MA MA041179A patent/MA41179A/fr unknown
- 2015-12-17 WO PCT/GB2015/054064 patent/WO2016097749A1/en not_active Ceased
- 2015-12-17 RU RU2017125520A patent/RU2017125520A/ru not_active Application Discontinuation
- 2015-12-17 JP JP2017532912A patent/JP6673920B2/ja active Active
- 2015-12-17 US US15/533,819 patent/US10508086B2/en active Active
- 2015-12-17 EP EP15813554.1A patent/EP3233845B1/en active Active
- 2015-12-17 CN CN201580075709.0A patent/CN107295799B/zh active Active
- 2015-12-17 AU AU2015365602A patent/AU2015365602B2/en active Active
- 2015-12-17 ES ES15813554T patent/ES2886471T3/es active Active
- 2015-12-17 BR BR112017012707-5A patent/BR112017012707B1/pt active IP Right Grant
- 2015-12-17 EP EP21179871.5A patent/EP3907224A1/en active Pending
- 2015-12-17 MX MX2017007976A patent/MX380901B/es unknown
- 2015-12-17 SG SG11201704843QA patent/SG11201704843QA/en unknown
- 2015-12-17 CA CA2969298A patent/CA2969298C/en active Active
- 2015-12-17 CN CN202110213641.5A patent/CN112979631B/zh active Active
- 2015-12-17 KR KR1020177019869A patent/KR102682782B1/ko active Active
-
2017
- 2017-06-07 IL IL252745A patent/IL252745B/en active IP Right Grant
- 2017-06-28 ZA ZA2017/04383A patent/ZA201704383B/en unknown
-
2019
- 2019-10-24 US US16/662,997 patent/US10995073B2/en active Active
-
2021
- 2021-03-17 US US17/204,206 patent/US12129236B2/en active Active
-
2024
- 2024-09-19 US US18/889,613 patent/US20250223266A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12129236B2 (en) | PARG inhibitory compounds | |
| US10239843B2 (en) | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | |
| AU2010214095B2 (en) | Novel amino azaheterocyclic carboxamides | |
| BRPI0618668B1 (pt) | Compostos inibidores dos receptores de tirosina quinase do tipo i, composições compreendendo tais compostos, e seus usos | |
| AU2018252251A1 (en) | Compounds useful as RET inhibitors | |
| AU2005321946A1 (en) | Enzyme modulators and treatments | |
| WO2019089835A1 (en) | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | |
| WO2012044090A2 (ko) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 | |
| WO2020150545A1 (en) | Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway | |
| WO2006040526A1 (en) | Quinazoline derivatives for use against cancer | |
| HK40063344A (en) | Parg inhibitory compounds | |
| HK1245253B (zh) | Parg抑制化合物 | |
| HK1244799A1 (en) | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg | |
| MX2008009811A (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |